Strategies for assessing renal function prior to outpatient contrast-enhanced CT: a UK survey by Harris, Martine A. et al.
 The University of Bradford Institutional 
Repository 
http://bradscholars.brad.ac.uk 
This work is made available online in accordance with publisher policies. Please refer to the 
repository record for this item and our Policy Document available from the repository home 
page for further information. 
To see the final version of this work please visit the publisher’s website. Access to the 
published online version may require a subscription. 
Link to publisher version: https://doi.org/10.1259/bjr.20160077  
Citation:  Harris MA, Snaith B and Clarke R (2016) Strategies for assessing renal function prior to 
outpatient contrast-enhanced CT: a UK survey. British Journal of Radiology. 89: 20160077. 
Copyright statement: © 2016 The Authors. Full-text reproduced in accordance with the 
publisher’s self-archiving policy. 
 
BJR © 2016 The Authors. Published by the British Institute of Radiology
Received:
21 January 2016
Revised:
8 August 2016
Accepted:
24 August 2016
http://dx.doi.org/10.1259/bjr.20160077
Cite this article as:
Harris MA, Snaith B, Clarke R. Strategies for assessing renal function prior to outpatient contrast-enhanced CT: a UK survey. Br J Radiol 2016;
89: 20160077.
FULL PAPER
Strategies for assessing renal function prior to outpatient
contrast-enhanced CT: a UK survey
1MARTINE ANN HARRIS, MSc, BSc (Hons), 1BEVERLY SNAITH, PhD, FCR and 1RUTH CLARKE, MSc, DCR
1Radiology, Mid Yorkshire Hospitals NHS Trust, Wakefield, UK
Address correspondence to: Miss Martine Ann Harris
E-mail: martine.harris@midyorks.nhs.uk
Objective: To identify current UK screening practices
prior to contrast-enhanced CT. To determine the patient
management strategies to minimize the risk of contrast-
induced acute kidney injury (CI-AKI) risk in outpatients.
Methods: An invitation to complete an electronic survey
was distributed to the CT managers of 174 UK adult
National Health Service hospital trusts. The survey in-
cluded questions related to local protocols and national
guidance on which these are based. Details of the
assessment of renal function prior to imaging and
thresholds for contrast contraindication and patient
management were also sought.
Results: A response rate of 47.1% was received. Almost
all sites had a policy in place for contrast administration
(n580/82; 97.6%). The majority of sites require a blood
test on outpatients undergoing a contrast-enhanced CT
scan (n5 75/82; 91.5%); however, some (15/75; 20.0%)
sites only check the result in patients at high risk and
a small number (7/82; 8.5%) of sites indicated that it
was a referrer responsibility. The estimated glomerular
filtration rate (eGFR) or serum creatinine (SCr) result
threshold at which i.v. contrast was contraindicated
varied and 19 different threshold levels of eGFR or SCr
were identified, each leading to different prophylactic
strategies. Inconsistency was noted in the provision of
follow-up blood tests after contrast administration.
Conclusion: The wide variation in practice reflects
inconsistencies in published guidance. Evidence-
based consensuses of which patients to test and
subsequent risk thresholds will aid clinicians identify
those patients in which the risk of CI-AKI is clinically
significant but manageable. There is also a need to
determine the value of the various prophylactic strat-
egies, follow-up regimen and efficient service delivery
pathways.
Advances in knowledge: This survey has identified that
further work is required to define which patients are high
risk, confirm those which require renal function testing
prior to contrast administration and how best to manage
patients at risk of CI-AKI. The role of new technologies
within this service delivery pathway requires further
investigation.
INTRODUCTION
In CT, contrast agents improve the visibility of internal
structures, but the beneﬁts of their use must be weighed
against the potential risks.1 It is suggested that the safe
administration of intravascular contrast requires knowl-
edge of the appropriate indications for its use as well as the
potential side effects and their management.2 Low-osmolar
iodinated contrast agents are associated with a low risk of
adverse effects of 0.15%,1 and the vast majority of patients
will have no sequelae.3 However, contrast-induced acute
kidney injury (CI-AKI) is an issue in patients with reduced
renal function, deﬁned as an abnormal baseline serum
creatinine (SCr) or low estimated glomerular ﬁltration rate
(eGFR).4 The potential impact ranges from a slight increase
in SCr to severe acute renal failure (ARF) with anuria.5 The
clinical implication of acute kidney injury (AKI), regardless
of causative factor, is a major patient safety challenge for
health care and a recent economic analysis put the annual
cost of AKI in England at .£1 billion.6
CI-AKI is ARF occurring within 24–72 h after injection of
iodinated contrast that cannot be attributed to another
cause.4 The International Society of Nephrology deﬁne CI-
AKI as a rise in SCr of $0.5mg dl21 ($44mmol l21) or
a 25% increase from baseline value, assessed at 48 h after
a radiological procedure.7 It is an iatrogenic disease and
the third most common cause of hospital-acquired ARF
after surgery and severe hypotension.4 However, studies
have failed to disentangle CI-AKI, directly caused by
contrast agents, from post-contrast AKI which develops
coincidentally after administration for a variety of rea-
sons.8 The major concern is that CI-AKI is most often
non-oliguric, and an asymptomatic transient decline in
renal function may go undetected.9
The pathogenesis of CI-AKI is not entirely clear, but in-
travascular contrast agents pass from the vascular compartment
through capillaries into the extracellular space and are sub-
sequently eliminated by glomerular ﬁltration. This results in
their concentration in the tubular lumen by water resorption.5 It
is suggested that CI-AKI is induced by prolonged vasocon-
striction, medullar ischaemia, oxidative stress and the direct
tubular toxicity of the contrast agent.10 CI-AKI is directly related
to a number of pre-existing patient risk factors including
chronic kidney disease (CKD), diabetes, advanced age, conges-
tive heart failure, hypertension, dehydration and concomitant
use of nephrotoxic drugs, all factors which can impact on renal
function.11 The most widely accepted index of renal function is
glomerular ﬁltration rate;7 natural ﬂuctuations can occur in SCr,
particularly at times of acute medical instability.5 Glomerular
ﬁltration rate can be estimated by taking into account SCr levels
and factors predictive of muscle mass including age, race and
female sex.12 It is also the basis of grading for CKD and its ﬁve
stages.13
Multiple international contrast agent guidelines, AKI pre-
vention documents and medicine product details advise on
best practice for the safe and effective administration of con-
trast agents.1,2,7,12,14–19 The driver for their publication has
been the global increase in the use of intravascular contrast
agents and their repetitive use in a large number of patients. All
the guidelines and advisory documents appropriate to the UK
have relative consistency in acknowledging comorbidities as
a risk and require assessment of these on an individual basis.
To date, two targeted approaches have aimed to reduce the
incidence of CI-AKI—ﬁrstly, identiﬁcation of risk factors and
secondly, pharmacotherapy, aimed at preventing CI-AKI;3
however, the value, and most effective delivery, of these
approaches is still unknown.
A recently published review20 of 24 guidance documents on the
prevention of CI-AKI included documents by radiologists,
interventionalists, nephrologists and multidisciplinary teams.
This evaluation suggested that the generous number of clinical
practice guidelines available makes it difﬁcult for clinical prac-
titioners to determine which provides the most appropriate
advice and whether the evidence is comparable in quality, i.e.
that bias has been addressed and the advice is clinically feasible.
The authors conclude that despite the volume of guidance,
a wide range of methodological quality was evident and there is
limited consensus on CI-AKI prevention and how guidelines
should be implemented.20
The purpose of this study was to identify the current practice
employed across the UK concerning the identiﬁcation and
minimization of CI-AKI risk in outpatients referred for contrast-
enhanced CT.
METHODS AND MATERIALS
An invitation to complete an electronic survey was distributed as
a paper letter to CTmanagers. The sample consisted of all adult
National Health Service (NHS) trusts (or health boards) in the
UK identiﬁed from UK Government statistics and national
hospital databases (n5 174). Although there are a number of
independent sector providers of imaging services, CT scanning is
not necessarily widespread amongst these and therefore, the
survey was focused at NHS provision.
The aim of the survey was to collect information that would
inform understanding of how renal function assessment prior to
contrast-enhanced CT in the outpatient population (including
primary and secondary care referrals) is currently undertaken.
To ensure that the survey was accessible and not too onerous for
the respondent, questions were limited to the screening and
patient management strategies used in the outpatient population.
Although further information such as technology, type of contrast
and dose management procedures would be interesting and rel-
evant, they were considered outside the scope of this survey.
The survey was designed to be completed by the team leader or
superintendent of the CT department with knowledge of the
current local guidance, protocols and techniques. Only the name
of the hospital trust was required, all other data were collected
anonymously and treated conﬁdentially. The survey ran from
mid-August to mid-October 2015. To increase participation,
non-responding organizations were sent a reminder letter
4 weeks before the survey closed.
The questions were developed in the Bristol online survey tool
(University of Bristol, UK) and were based on initial literature
review and international guidance. The survey included a com-
bination of closed and open-ended questions to allow elabora-
tion where appropriate and a greater depth of information to be
collected. Departments were asked whether renal function is
assessed prior to scan and what current local protocols are in
place for i.v. contrast administration in patients who may have
impaired renal function. Questions were related to the speciﬁcs
of renal function screening and particularly about who refers for
any blood tests and timescales for the management of results.
Thresholds for contrast contraindication and patient manage-
ment were also sought. To ensure that the survey was robust,
clear and ﬁt for purpose, the questions were developed by
a multiprofessional team and piloted prior to distribution, with
minor changes made to improve comprehension.
Survey responses were downloaded into Excel® (Microsoft
Corporation, Redmond, WA) for the descriptive analysis and
identiﬁcation of themes from the free-text responses. All data
have been kept conﬁdential and all are anonymized in study
reporting. Mandatory questions were answered by all respond-
ents; where there was an option for non-response to speciﬁc
questions, these have been highlighted in the results.
Local research approval to carry out this work was obtained.
This approval certiﬁed that ethical approval was not required in
this case.
RESULTS
A total of 85 responses were received within the assigned
timescale; 3 responses were duplicates and were removed,
leaving 82 responses for analysis, a response rate of 47.1%. A
geographical breakdown of responses conﬁrmed the lowest re-
sponse rate to be from England (Table 1).
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Almost all sites conﬁrmed that a policy was in place for contrast
administration within radiology (n5 80/82; 97.6%). Some in-
dicated that their policy was currently under review and cited
recently published guidance as the reason. The majority in-
dicated alignment with at least 1 national and/or international
guideline (n5 64/80; 80%), although there was no consistency
between respondents. The most common reference was to the
Royal College of Radiologists (RCR) contrast guidelines (n5 52/
64; 81.3%), although a large number of sites (n5 41/64; 64.1%)
did not include the edition number; a small number of sites
speciﬁcally referred to the 2005 or 2010 versions. Four sites were
unsure which national guidance was being followed.
With regard to the assessment of renal function, the large ma-
jority of sites require a blood test on outpatients undergoing
a contrast-enhanced CT scan (n5 75/82; 91.5%). Most review
all patients (n5 60/75; 80.0%); however, a number of sites (15/
75; 20.0%) only check those identiﬁed as high risk, with free-
text comments describing risk factors including diabetes (n5 5)
and vascular (n5 1) or older people (n5 6), although for the
latter, the cut-off varied from 60 to 75. A small cohort (7/82;
8.5%) indicated that this was considered solely the referrer re-
sponsibility, with no radiology conﬁrmation or review of the
renal function; all stated they were following RCR guidance,
although the edition varied.
Of the 75 sites that assess renal function, variation in who takes
responsibility for organizing blood tests was noted. Many expect
referring clinicians (n5 28/75; 37.3%) to organize the test;
a small number of radiology departments (n5 5/75; 6.7%)
perform this function and the remainder share responsibility.
In relation to the reviewing of blood test results by radiology,
over half of the sites check the results at the justiﬁcation (vet-
ting) stage (n5 42/75; 56.0%), or when the appointment is
made (n5 12/75; 16.0%), with any patient who still required
blood tests being rechecked prior to the scan. A number of
respondents (n5 21/75; 28.0%) indicated the results are
reviewed on the day of the scan, or the night before if staff-
ing allows.
Variation in the acceptable timeframe of blood test results was
noted (Table 2), although 3 months was the most common value.
There was inconsistency in the renal function measures used
between the 75 sites, with approximately half (n5 38/75; 50.7%)
using eGFR and a smaller number (n5 8/75; 10.7%) using SCr
only. The remaining sites (n5 29/75; 38.7%) identiﬁed both
tests to be in use.
Where patients present without recent bloods tests available,
a range of scenarios were described, with some ensuring a blood
test is performed, using either point-of-care (POC) technology
or standard pathology blood test, continuing with the scan in
patients at low risk only, whereas others would seek the advice
from a consultant radiologist (Table 3). Four sites indicated this
situation would never occur, as an appointment would not be
made until a renal function test result was available.
The eGFR or SCr result threshold at which i.v. contrast was
contraindicated varied between organizations, with a number of
sites (n5 19/75; 25.3%) not identifying cut-off values (Table 4).
One site indicated that this threshold level could depend on the
individual radiologist asked for advice, with eGFR levels of
35mlmin21/1.73m2 and 45mlmin21/1.73m2 being accepted
by different radiologists. Another indicated that an eGFR
,30mlmin21/1.72m2 could be overruled on the grounds of
urgency, but that a formal prescription for the i.v. contrast must
be completed by the advising consultant radiologist.
The questionnaire sought to identify whether there were levels
at which the scan could proceed but with changes in patient
management. Many sites had multiple options in place; however,
no consistent approach was identiﬁed, with interventions vary-
ing between sites and blood test result levels. Overall, 19 dif-
ferent threshold levels of eGFR or SCr were identiﬁed, each
leading to different prophylactic strategies. Five sites stated both
SCr and eGFR threshold values, but the majority of respondents
stated a single measure. No regional differences in patient
management strategy were identiﬁed for those patients
Table 1. Geographical breakdown of responding organizations
Geographical region Response number (%)
England 67 (45.0)
East Midlands 1
Eastern 5
London 6
North east 7
North west 14
South east 11
South west 9
West Midlands 3
Yorkshire and Humberside 11
Northern Ireland 4 (80.0)
Scotland 7 (50.0)
Wales 4 (66.7)
Total 82 (47.1)
Table 2. Timescale for blood test results for those requiring
results prior to contrast administration
Timescale (months) Sites no. (%)
Within 1 6 (8.0)
Within 2 4 (5.3)
Within 3 48 (64.0)
3–6 15 (20.0)
.6 2 (2.7)
Total 75
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identiﬁed at high risk of CI-AKI from this study. A combination
of oral, i.v. hydration or pharmacological intervention is evident
within every region of the countries surveyed. This was carried
out independent of, or in conjunction with, advice from con-
sultant radiologists.
Prophylactic hydration of patients was a common strategy, but its
use and approach varied. One site stated there was no level of
absolute contrast contraindication as at eGFR,30mlmin21/
1.73m2, patients were admitted for the day and treated with i.v.
sodium bicarbonate, whereas patients with eGFR 30–45mlmin21/
1.73m2 were advised to orally hydrate at home. Another three
sites had a similar policy, but i.v. hydration could be provided for
patients with eGFR ,40 or 45mlmin21/1.73m2, respectively,
with one site identifying that patients would be hydrated with oral
N-acetylcysteine or i.v. sodium bicarbonate. Two sites indicated
that all outpatients orally hydrated before i.v. contrast as standard;
another also advised post-scan hydration in patients with an
eGFR result of 30–44mlmin21/1.73m2. Where the eGFR level
was between 30 and 60mlmin21/1.73m2, there was an equal
preference to orally or intravenously hydrating the patient or
consult the individual radiologist supervising that list.
A number of sites indicated that there was variation between
patients at low risk and those at high risk, including different, and
inconsistent, management strategies for those with diabetes and
older persons. Changing osmolality of the contrast was men-
tioned by one respondent and a further site advocated a potential
reduction in contrast volume from 100 to 75ml where the SCr
was over 130 (or eGFR was ,59mlmin21/1.72m2).
Further inconsistency was noted in the provision of follow-up
blood tests after i.v. contrast administration. Of the 56 sites
providing information, 4 sites responded that all patients would
be followed up, whereas at 19 sites, patients would never have
a follow-up blood test. The remaining sites indicated that some
patients would be included, often limited to those at high risk.
However, for those sites expecting follow-up blood tests, orga-
nization arrangements varied, with 44.6% (n5 25/56) sites
delegating this responsibility to the patients’ GP, and a further
23.2% (n5 13/56) sites expecting the referrer to take this re-
sponsibility. Five sites did not state who was responsible for
obtaining follow-up blood tests. Five sites did not state who was
responsible for obtaining follow-up blood tests, with the
responsibility varying on a case-by-case basis between radiology,
the GP or the referrer at the remaining 13 (23.2%) sites.
DISCUSSION
This study has identiﬁed diversity in practice across the UK
concerning the implementation of published guidelines for the
use of iodinated contrast agents. Although 80% of responding
sites conﬁrmed that their local policy aligned with national or
international guidance, we identiﬁed the use of eight different
guidelines and a number of outdated publications. This incon-
sistency is in keeping with a recent survey of radiotherapy
centres by Williams and Probst.21 This makes correlation be-
tween guidance and practice almost impossible for clinical
practitioners. This survey identiﬁed that the most common
guidelines in use across the UK were those published by the
RCR. The most recent (third) edition of these guidelines was
released in 2015,1 although worryingly, some respondents were
still referring to the ﬁrst and second editions. In keeping with
a previous review,20 the current UK guidelines identiﬁed are
based on a range of conﬂicting evidence, including terms, def-
initions, variation in suggested risk factors, reliable cut-off
Table 3. Action taken when patient presents with no blood
results available
Action taken Site no. (%)
Blood test arranged
POCa test is completed 8 (11.3)
Send for blood test and scanned same day (if
possible)
17 (23.9)
Send for blood test then scan reappointed on
a different day
15 (21.1)
Risk stratiﬁcation
Low risk, continue with scan; high risk, blood
test and reappoint
5 (7.0)
Low risk, continue with scan; high risk, ask
radiologist
3 (4.2)
Ask a consultant radiologist 21 (29.6)
Scan continues 1 (1.4)
Scan continues, but patient advised to
hydrate post-scan
1 (1.4)
Total 71
aPOC, point of care (creatinine).
Table 4. Renal function threshold at which i.v. contrast was
contraindicated
Blood test result Sites no. (%)
eGFR
,15 1 (1.3)
#20 2 (2.6)
,30 35 (45.4)
,35 1 (1.3)
,40 8 (10.4)
,45 2 (2.6)
SCr
.140 1 (1.3)
.150 2 (2.6)
.160 1 (1.3)
.200 3 (3.9)
.250 2 (2.6)
No level identiﬁed 19 (24.7)
Total 77a
eGFR, estimated glomerular filtration rate; SCr, serum creatinine.
aTwo sites provided both eGFR and SCr levels; seven sites do not
check bloods.
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points for identifying patients at risk for CI-AKI and the ef-
fectiveness of management strategies. There is, however, an
agreement across guidelines that the risk of contrast adminis-
tration must be weighed against the risk of diagnostic error from
a non-contrast scan.22 It is suggested discussion with a renal
physician should form part of the beneﬁt assessment;2 however,
practically, this may be difﬁcult for hospitals without on-site
renal services.
There is an increasing difference in opinion between medical,
nephrology and cardiology specialities and their radiology col-
leagues as to whether CI-AKI is a true risk in patients with
moderate to severe renal dysfunction.8 Indeed, the incidence and
signiﬁcance of CI-AKI has been questioned in multiple radiol-
ogy studies,23–27 the latest of which utilized propensity scores to
compare the incidence of AKI rate between patients who had
undergone contrast-enhanced or non-contrast CT scans.25 Some
suggest that contrast agents are not a nephrotoxic risk in those
with a stable eGFR of $45mlmin21/1.73m2.27 Potentially,
many factors contribute to the development of CI-AKI, re-
gardless of the iodinated contrast material;26 thus, further large-
scale prospective RCT studies have been suggested to identify the
actual risk. This deﬁnitive evidence would have to take into
account the confounders pre- and post-contrast administration
and control the selection bias identiﬁed to date,8,22,28 but this
may not be ethically feasible.
Evidence suggests that the risks of developing CI-AKI are
greatest in patients with ARF or established CKD.8,23 Screening
is therefore highly recommended and renal function assess-
ment for all outpatients undergoing routine CT imaging is
advocated by ﬁve of the eight guidelines cited by
respondents.1,2,7,14,18 There is, however, a suggestion, sup-
ported by the American College of Radiology (ACR),16 that
this is only necessary in those with risk factors for the de-
velopment of CI-AKI, a stance adopted by 15 sites in this
survey. A recent survey of radiotherapy centre CT provision
also demonstrated variation between testing all patients vs
testing those at high risk only.21 Conclusive evidence that renal
function testing is required only in patients at high risk would
make a signiﬁcant impact on workloads, thereby streamlining
CT services and waiting times for scan. Unfortunately, this
evidence has yet to be produced and the question still remains
should blood tests be performed on everyone or on patients at
high risk only?
Ensuring referrers provide adequate information to assess
whether the patient is at high or low risk of CI-AKI is vital to
ensure the renal function is assessed at the appropriate time. This
provides an ongoing challenge for radiology departments and can
potentially lead to delays in diagnostic pathways and treatment
decisions. It is clear from the responses to this survey that a small
number of sites refuse to process referrals until this information is
available. Perhaps a more pragmatic approach is to seek comor-
bidity information from the patient, with European Society of
Urogential Radiology (ESUR)14 and Kidney Disease: Improving
Global Outcomes (KDIGO)7 guidelines recommending a screen-
ing questionnaire in outpatient studies where renal function data
are not available.
Nephrology colleagues may consider it worrying that seven ra-
diology departments did not assess renal function in any patients
prior to contrast administration, despite stating that their local
protocol aligned with RCR guidance. For those sites assessing
renal function prior to CT scan, the majority appeared to cor-
relate to the recommended 3 months stated by the RCR.1 Some
sites preferred more stringent timeframes, requesting that blood
tests be within preceding the 1 or 2 months, whereas others
accepted blood tests up to 6 months old, timescales not advo-
cated within any guidance. No sites followed the ESUR guidance,
which speciﬁes that a blood test is required within the 7 days
prior to a scan.14 Unhelpfully, other guidance documents do not
identify a time period within which renal function assessments
are considered acceptable.2,7,17
Our survey also found non-standardization of measures for
renal function, although the guidance listed by the respondents
consistently state the eGFR is the standard measure to be used in
the stable outpatient population; eight sites use SCr. The guid-
ance states that SCr is the preferred measure in the patient who
is acutely unwell, most commonly referred to as emergency
department or inpatient referrals.1,2 Within the literature there is
no deﬁnitive eGFR threshold below which the risk for CI-AKI
increases7 and there is a wide variation in risk thresholds, pro-
phylactic strategies and complete contraindication levels being
applied at a clinical level. Regardless of geographical location or
guidance being followed, it appears that the ﬁve stages of CKD
are being used as a proxy for patient management decisions.
National Institute for health and care Excellence (NICE) guid-
ance for CKD13 identiﬁes a threshold risk of 40mlmin21/
1.73m2 for CI-AKI, the same as the RCR guidance,1 supporting
the practice of eight of the sites surveyed.
The risk of CI-AKI increases at advanced stages of CKD and
the majority of hospitals stated that contrast was contra-
indicated at an eGFR below 30mlmin21/1.73m2. This de-
cision may be attributed to patients being classed as having
severely reduced kidney function with an eGFR of
15–29mlmin21/1.73m2, i.e. Stage 4 CKD.1,13 This practice is
supported by Davenport et al,8 who state that patients with an
eGFR of 30mlmin21/1.73m2 or less are considered to be at
substantially increased risk of AKI or no risk. If applying NICE
CKD staging, patients with an eGFR of 30–44mlmin21/
1.72m2 (Stage 3b) are described as having moderately reduced
kidney function and are at borderline risk of CI-AKI;13 this
corresponds with KDIGO guidance7 and literature27 that
suggests the risk of CI-AKI becomes clinically important at
eGFR ,45mlmin21/1.73m2. In the absence of consensus, we
are applying unnecessary and possibly inappropriate pro-
phylactic measures in some patients, resulting in increased costs
and day case admissions, while missing a large cohort of patients
who would beneﬁt from precautionary care.20 A single re-
spondent indicated that no eGFR threshold existed for contrast
administration, and it was at the discretion of the responsible
radiologist to overrule levels if there is a clinical beneﬁt for its
use. A number of guidance documents recommend that where
contrast is contraindicated, alternative imaging methods should
be considered and a discussion between radiology and the re-
ferring clinician to assess the risk–beneﬁt should be
Full paper: UK strategies for assessing renal function prior to contrast CT BJR
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undertaken.1,2,7 However, in current practice and working to
imaging targets, it is likely that this decision is made unilaterally.
Where departmental policies state that renal function should be
assessed prior to the administration of contrast agents, difﬁ-
culties occur when patients attend without a recent blood test. A
recent study demonstrated the potential scale of this problem
when it was estimated that this occurred in 5.3% of patients.29
The scenarios described within our study whereby patients are
sent for a blood test and scanned later increase patient waiting
times and waste scanner capacity. With increasing pressure to
reduce waiting times in radiology30 and an annual increase in
demand by 10.3% per year over the past 10 years,31 it is im-
portant that strategies are in place to assess renal function within
the required timescales. The practice of asking a radiologist for
advice also ties up valuable stafﬁng resources and this is further
compounded with suggestions that this may not result in con-
sistent patient management decisions. In addition, many CT
departments are undertaking outpatient examinations 7 days
a week and a greater number of sessions are undertaken without
either a designated radiologist or even one on the hospital
premises. This would justify why 56.0% of respondents prefer to
check renal function status before booking appointments.
The issues may be compounded for patients referred to tertiary
centres for scans outside of their geographic region. The use of
new POC technologies to assess renal function was almost in-
stantaneous; they were in use by 11.3% of the sites surveyed and
may potentially provide a solution. It has been suggested that
having access to POC testing may allow CT departments to
make rapid assessment of renal function and identify those at
risk of CI-AKI, as well as patients who may have developed AKI
post-contrast administration to plan their management.9 How-
ever, the widespread use of POC would require adequate
resources available to undertake these tests, and further research
into their implementation in UK radiology departments is
required.
Although many centres orally hydrate outpatients in the hope of
preventing CI-AKI, current recommendations are not to solely
use oral ﬂuids in patients at increased risk of AKI.7 The rationale
for hydration is to prevent the renal vasoconstriction and sub-
sequent hypoxia caused by contrast agents,11 which are greatest
in those who are dehydrated. While this may not justify the
current practice of CT departments, it explains the protocols for
orally hydrating all or some patients. There is currently in-
sufﬁcient evidence to show that this is an effective prophylaxis;
in fact, KDIGO7 and RCR guidance1 state that i.v. hydration
should be given for volume expansion with sodium chloride or
sodium bicarbonate to reduce CI-AKI in patients at increased
risk. Oral N-acetylcysteine has also been suggested in combi-
nation with i.v. volume expansion,32 although the effectiveness
of i.v. hydration remains under question and further research is
required.33,34 Interestingly, current research is also exploring the
efﬁcacy of oral salt capsules and water as an alternative pro-
phylactic strategy.35
Many of the guidelines1,2,7 suggest other practical methods of
reducing the risk of CI-AKI. These include using low-osmolar
or isomolar contrast, patient weight-speciﬁc contrast dose, re-
ducing the tube voltage to improve image contrast or a saline
chaser.36 Early-stage research into biomarkers suggests that
many nephrons may be injured each time contrast is injected28
and repeated doses of contrast within 48 h are to be avoided.36
Many guidelines do not specify a follow-up regime for patients
who have received a dose of i.v. contrast agent. However, they
are advocated in the guidance issued jointly by the Renal As-
sociation, British Cardiovascular Intervention Society and RCR,1
who recommend that renal function should be checked within
48–72 h of contrast administration in patients at high risk.
Neither guidance speciﬁes who should take responsibility for
organizing this post-contrast blood test and actions following
the result. Few radiology departments have procedures in place
for the follow-up assessment of renal function after i.v. contrast
administration for outpatient CT. For sites considering whether
to implement this, there is still debate as to the most appropriate
timing. Ribichini et al37 suggest that CI-AKI can be predicted at
12 h and therefore, a follow-up blood test within 48 h would
enable early intervention. Their study found that 18% of
patients may have developed CI-AKI during this peak period;
however, the same study also showed that 7% of patients
maintained some level of renal insult at 30 days. SCr levels
should return to baseline level within 10–14 days;4 however, in
severe cases, it is said that SCr may not peak until 3–5 days after
contrast exposure. It has been suggested that measurement of
renal function at 72 h may potentially underestimate CI-AKI in
comparison with those taken over a longer time period.38 The
practicalities of radiology departments following up the results
of these tests and ensuring correct care for patients who have
developed CI-AKI may be problematic, given the number of
contrast-enhanced CT examinations currently undertaken in the
UK. It is therefore not surprising that the majority of sites with
a follow-up regimen in place currently delegate this task to the
referrer or patients’ GP. The utilization of POC testing may have
the potential to aid the monitoring of renal function post-
contrast administration, but service delivery pathways will re-
quire clear and appropriate delegation of responsibility as well as
effective communication pathways between the multiprofes-
sional team to facilitate this practice.
LIMITATIONS
The response rate within England is a limitation and means that
the results are incomplete. Marked variation in practice is evident
even within the responding cohort, but we are unable to ascertain
whether this would have been compounded by a higher response.
Further, the population was limited to NHS organizations and
therefore, the data are further limited in demonstrating total
UK practice. The screening strategies sought in this study were
focused on the performance of renal function blood tests. A
small number of sites offered information on pre-examination
risk questionnaires that were in use as part of local policy.
However, as this was not a speciﬁc question, how widespread
this practice may be is unclear; however, these may provide
a means of identifying patients at high risk.
No patterns could be identiﬁed in terms of region, but no
statistical analysis could be performed as evidence owing to
BJR Harris et al
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the low number of responses from some regions; however, it
is clear that practice appears not to be related to geographical
location.
CONCLUSION
The wide variation in practice demonstrated in this survey
reﬂects, and may be directly attributable to, inconsistencies in
published guidance. The guidance details current best practice
for the safe administration of contrast agents to adults; how-
ever, these standards must be feasible in today’s high-demand
clinical arena. Decisions should be made on an individual basis
for those with some level of renal insufﬁciency following
careful assessment of risk–beneﬁt and in conjunction with
a multidisciplinary team. However, the discordance in the lit-
erature has two clear arms—that published by the radiology
community and those with renal physician input; a single
internationally accepted evidence-based guideline is essential to
develop local clinical protocols.
This survey has identiﬁed that further work is still required to
deﬁne what constitutes a patient to be at high risk. We have
demonstrated that it is common UK practice to assess renal
function on all outpatients prior to contrast-enhanced CT
studies, but it is not yet known as to whether this a true re-
quirement or excessive caution. Evidence-based consensus on
who to test and subsequent risk thresholds will aid clinicians in
identifying those patients in whom the risk of CI-AKI is
clinically signiﬁcant but manageable. There is also a need for
further research to determine the true value of the various
prophylactic strategies being implemented, as well as the ap-
propriate follow-up regimen and efﬁcient service delivery
pathways.
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